Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Had 1 or more pharmacy claim for apixaban or warfarin or dabigatran or rivaroxaban during the identification period (01-Jan-2013 to 30-Sep-2015). The first OAC pharmacy claim date during the identification period will be designated as the index date
•2. Patients 18 years old or older as of the index date
•3. At least 1 diagnosis of atrial fibrillation prior to or on index date, identified by any medical claim
•4. At least 12 months of baseline period prior to index date with continuous enrollment

•1. Evidence of valvular heart disease, transient atrial fibrillation, venous thromboembolism during the 12-month baseline period or on the index date
•2. Evidence of pregnancy during the study period
•3. Had a pharmacy claim for warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban during the 12-month baseline period
•4. Had more than 1 oral anticoagulant claim on the index date

Related studies

NCT05232643 · Non-Valvular Atrial Fibrillation (NVAF)

NCT04559243 · Non-valvular Atrial Fibrillation, Embolic Stroke

NCT05565599 · Non-valvular Atrial Fibrillation

NCT05567172 · Non-valvular Atrial Fibrillation (AF)

NCT03887780 · Non-valvular Atrial Fibrillation (NVAF)

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation